1. Introduction {#sec1}
===============

The application of endomyocardial biopsy (EMB) has shown that some nonischemic heart failures are associated with myocardial disease, among which myocarditis and dilated cardiomyopathy are the most common. Although the pathogenesis of nonischemic cardiomyopathy remains unclear, it is known that these diseases are most commonly caused by microbial infections (e.g., viruses) and autoimmune diseases \[[@B1]\], with physical and chemical factors (e.g., alcohol) and the side effects of drugs, also contributing to a lesser extent.

It has recently been shown that viral populations in the myocardium are constantly changing \[[@B2]\] and our understanding of the pathophysiological processes that lead to myocardial disease are gradually improving. In a comparison of patients before and after treatment through the performance of a second myocardial biopsy, Kuhl et al. \[[@B3], [@B4]\] found that the cardiac function showed greater recovery in patients who changed from virus-positive to virus-negative than in those who continued to be virus-positive, and so considered that the persistence of the virus was a predictor of prognosis. However, to the best of our knowledge, there has been no meta-analysis or systematic review of the impact of viruses on the prognosis of myocardial disease and no assessment of whether cardiomyocytes contribute to the assessment of clinical outcomes.

The purpose of this study was to examine the role viruses play in myocarditis and dilated cardiomyopathy, and to evaluate whether the presence or absence of viruses has potential value as a predictor of the nontransplant survival rate.

2. Materials and Methods {#sec2}
========================

2.1. Search Strategy and Selection Criteria {#sec2.1}
-------------------------------------------

Prospective and retrospective cohort studies relating to suspected myocarditis or idiopathic cardiomyopathy, myocardial biopsy, and the detection of viruses that were published between January 1, 1964 and August 14, 2018 were searched for in Embase, PubMed, and the Cochrane library using the search keywords "congestive cardiomyopathy," "dilated cardiomyopathy," "cardiomyopathy," "myocarditis," "carditis," "myocardial biopsy," "endomyocardial biopsy," "cardiac biopsies," and "heart muscle biopsy." The literature search was undertaken independently by two of the authors (Wen-Hao Chen and You-Sheng Guo) and citation searches were also made on related articles to ensure a complete literature search had been undertaken. The full text of each article that was retrieved was examined by two reviewers (Huan-Ji Zhang and Dong-Hui Zhang) to determine whether the study met the inclusion criteria (see below). A review of the full text and the final selection of articles for inclusion in this study was then completed by one of the authors (Wen-Hao Chen).

2.2. Inclusion and Exclusion Criteria {#sec2.2}
-------------------------------------

Research needed to meet the following criteria for inclusion in this study: (1) cohort study; (2) patients over 18 years of age with suspected myocarditis or dilated cardiomyopathy; (3) accepted myocardial biopsy and detection of a virus in the myocardial tissues.

Any study that met one or more of the following criteria was excluded: (1) nonenglish literature, conference summary, or case report; (2) patients less than 18 years of age, with coronary heart disease (coronary stenosis \> 50%) or no myocardial biopsy; (3) heart transplant or clear pathogenesis factors (e.g., cardiac amyloidosis, peripartum cardiomyopathy, human immunodeficiency virus (HIV) infection, systemic lupus erythematosus); (4) no virus-negative control group or an inability to extract key data.

The main outcomes were death, heart transplantation, and hospitalization due to fatal arrhythmia or heart failure. If a study reported both cardiovascular-related deaths and all-cause death endpoints, the former was preferred.

2.3. Quality Assessment {#sec2.3}
-----------------------

The Newcastle-Ottawa scale (NOS) was applied to all studies that met the inclusion criteria. The NOS assesses studies based on three major elements (selection, comparability, and outcome), which can attain maximum scores of 4, 2, and 3 stars, respectively, to give an overall maximum score of 9 stars \[[@B5]\]. It is generally considered that a study needs to attain a score of \>6 stars to be considered high quality. The NOS is highly versatile and reliable and is often recommended for evaluating the quality of cohort studies by the Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 \[[@B6]\]. The scoring process was completed by two of the authors (Dong-Hui Zhang and Huan-Ji Zhang). When there was inconsistency in the quality evaluation, another author (Wen-Hao Chen) decided which score to adopt.

2.4. Data Extraction {#sec2.4}
--------------------

The following data were extracted from each of the articles that was included in this study: the first author\'s name, year of publication, country, study design, following period, groups and number of patients, age, initial diagnosis, methods of virus detection and viral types, outcomes, and any information about the article\'s quality. Survival data were usually provided as the heart transplant-free survival rate. In addition, the hazard ratio (HR), *p*-value, Kaplan--Meier survival curve, and 95% confidence interval (95% CI) were obtained from related articles. Where results from the same study for a particular risk factor had been published in more than one manuscript, the paper with the most complete data was used or, where the data were the same, the results from the most recent publication were used. This process was completed by You-Sheng Guo.

2.5. Data Synthesis {#sec2.5}
-------------------

The results are presented as the log hazard ratio (logHR) and the standard error (SE), which in some cases could be extracted directly from the articles. Where no specific data were provided for the HR and 95% CI, the logHR and SE were calculated by extracting Kaplan--Meier survival curves using Engauge Digitizer version 10.1 following Tierney\'s software guidance \[[@B7]\].

Heterogeneity was defined as *I*^2^ \> 50% or *P* \< 0.10. A fixed effects model can be used where no heterogeneity is detected, whereas a random effects model should be used where heterogeneity is statistically significant. The weight of each study was calculated using the inverse variance method and was adjusted in the effects model. Outcomes for the virus-positive and virus-negative groups were compared by examining the HR and 95% CI: if HR was \>1 and the 95% CI did not contain 1, then the two groups were significantly different, with the virus-positive group having a poorer outcome than the virus-negative group. All of the above analyses were presented using RevMan5.3. In addition, publication bias was examined by performing Egger\'s test in Stata12.

3. Results {#sec3}
==========

3.1. Characteristics of the Selected Studies {#sec3.1}
--------------------------------------------

In total, we scanned 9183 articles from PubMed, Embase, and the Cochrane library, 9111 of which were excluded as a result of the removal of duplicates and record screening (no mention of a virus, case report, review, comment, conference abstract, nonenglish publication, related to children, heart transplantation, HIV infection, peripartum cardiomyopathy). Full-text review resulted in a further 62 articles being excluded due to an unsuitable subject, no relevant endpoint, no control group, or no survival data or because they were a review or from the same study as another report. This resulted in 10 articles that included 1006 patients with suspected myocarditis or dilated cardiomyopathy confirmed by EMB being selected for inclusion in the meta-analysis: (1) Why et al. \[[@B8]\], (2) Figulla et al. \[[@B9]\], (3) Fujioka et al. \[[@B10]\], (4) Caforio et al. \[[@B11]\], (5) Kindermann et al. \[[@B12]\], (6) Nowalany-Kozielska et al. \[[@B13]\], (7) Tebbe et al. \[[@B14]\], (8) Karatolios et al. \[[@B15]\], (9) Kuethe et al. \[[@B16]\], and (10) Hjalmarsson et al. \[[@B17]\]. The screening process is shown in [Figure 1](#fig1){ref-type="fig"} and the characteristics of the selected studies are provided in Tables [1](#tab1){ref-type="table"} and [2](#tab2){ref-type="table"}.

The quality scores of the 10 studies ranged from 7 to 9 ([Table 3](#tab3){ref-type="table"}), indicating that they were all high-quality studies according to the NOS. Only 3 of the 10 studies provided HR values and 95% CIs. Therefore, we used Tierney\'s method \[[@B17]\] (as recommended by the Cochrane Handbook) to extract the number of people, the number of events, and the Kaplan--Meier curve from each article, allowing us to calculate the HR value and its interval. Five of the studies were from Germany, while one was from each of Japan, Italy, the United Kingdom, Poland, and Switzerland, and none of the studies were included in other publications. The sample sizes ranged from 26 to 293 patients, with a total of 440 patients in the virus-positive group and 566 patients in the virus-negative group. The shortest follow-up period was only 6--12 months \[[@B9]\], while the longest was 112 ± 57 months \[[@B16]\].

Regarding the baseline data from the 10 cohort studies, Figulla et al. \[[@B9]\] reported that atrial fibrillation was more common in the virus-positive group than in the virus-negative group (35% vs. 14%, respectively; *P* = 0.04) and that the myofibril volume fraction also significantly differed between the two groups (57.5 ± 4.3 vs. 55.1 ± 3.1, respectively; *P* = 0.036). Furthermore, Caforio et al. \[[@B11]\] reported that clinical left heart failure and right heart failure were more common in the virus-positive group than in the virus-negative group (*P* = 0.005 and 0.01, respectively). However, there were no statistically significant differences between the groups in any of the other cohort studies. Only Kindermann et al. \[[@B12]\] reported cardiac mortality and all-cause mortality as the primary endpoint (priority of cardiac-related deaths), with all other studies reporting all-cause mortality and heart transplantation.

3.2. Long-Term Prognosis of Virus-Positive Patients {#sec3.2}
---------------------------------------------------

A high level of heterogeneity was observed in the dataset (*I*^2^ = 47%, *P* = 0.05), so we used a random effects model to analyze the data. This showed that there was no significant difference in long-term prognosis of patients with virus-positive and virus-negative myocardial tissue (HR = 1.40, 95% CI = 0.93--2.12, *P* = 0.11; [Figure 2](#fig2){ref-type="fig"}).

3.3. Sensitivity Analysis {#sec3.3}
-------------------------

To examine the source of the heterogeneity in the dataset, we performed a sensitivity analysis. We found that the removal of Figulla et al.\'s study \[[@B8]\] caused the heterogeneity to decrease from *I*^2^ = 47% (*P* = 0.05) to *I*^2^ = 22% (*P* = 0.25) and led to a significant difference in the long-term prognosis of the virus-positive and virus-negative groups (HR = 1.52, 95% CI = 1.08--2.13, *P* = 0.02, *n* = 9). Therefore, we performed a subgroup analysis to further explore the source of heterogeneity.

3.4. Subgroup Analysis {#sec3.4}
----------------------

### 3.4.1. Specific vs. Nonspecific Treatment {#sec3.4.1}

In Figulla et al.\'s study \[[@B9]\], four patients in the virus-positive group had progressive deterioration of cardiac function but this improved after the administration of interferon alpha, and the same treatment was also used by Karatolios et al. \[[@B15]\]. Therefore, subgroup analysis was performed for this treatment. We found that in the absence of specific treatment, the virus-negative group was associated with a better prognosis than the virus-positive group (HR = 1.40, 95% CI = 1.06--1.86, *P* = 0.002; [Figure 3](#fig3){ref-type="fig"}).

### 3.4.2. Polymerase Chain Reaction (PCR) vs. NonPCR Technology {#sec3.4.2}

Neither Why et al. \[[@B8]\] nor Figulla et al. \[[@B9]\] used PCR technology in the detection of viruses in the myocardial tissue, instead using molecular hybridization and in situ hybridization, respectively. By contrast, the other eight studies used more sensitive PCR techniques to detect viral DNA or RNA. However, we found that while the use of PCR technology could explain some of the heterogeneity, it did not affect the overall outcome (HR = 1.32, 95% CI = 0.99--1.74, *P* = 0.05; [Figure 4](#fig4){ref-type="fig"}).

### 3.4.3. Left Ventricular vs. Right Ventricular EMB {#sec3.4.3}

Seven of the studies carried out left ventricular EMB, while three performed right ventricular EMB. Among the former studies, only Kindermann et al. \[[@B12]\] performed the puncture under cardiovascular magnetic resonance imaging (CMR) and echocardiography. The subgroup analysis indicated that virus-negative right ventricular tissue was a protective factor for a good prognosis (HR = 2.08, 95% CI = 1.07--4.04, *P* = 0.03; [Figure 5](#fig5){ref-type="fig"}).

### 3.4.4. Myocarditis and Dilated Cardiomyopathy {#sec3.4.4}

Myocarditis is generally considered to be one of the causes of progression to dilated cardiomyopathy. The preliminary diagnosis of the population in this study includes myocarditis and dilated cardiomyopathy. We try to group these two diagnoses and have a subsequent meta-analysis to find out the relationship between different prognosis and myocardial viral infection. The results showed that the prognosis was not related to whether the myocardium was infected with virus in neither myocarditis group nor dilated cardiomyopathy group. (Myocarditis group HR = 1.57, 95% CI = 0.91--2.72, *P* = 0.10; Dilated Cardiomyopathy HR = 1.22, 95% CI = 0.60--2.50, *P* = 0.58; [Figure 6](#fig6){ref-type="fig"}).

3.5. Publication Bias {#sec3.5}
---------------------

We found that there was no publication bias using Egger\'s test (*P* = 0.407; [Figure 7](#fig7){ref-type="fig"} and [Table 4](#tab4){ref-type="table"}).

4. Discussion {#sec4}
=============

In this meta-analysis, data from 10 cohort studies that included a total of 1006 patients with suspected myocarditis or dilated cardiomyopathy who underwent EMB were used to compare the long-term prognosis of patients with virus-positive and virus-negative myocardial tissue. The pooled results suggested that virus-positive patients did not have a worse prognosis than virus-negative patients, which is similar to the findings of most cohort studies. However, we believed that these results were not entirely reliable due to the high level of heterogeneity in the dataset (although the random effects model was used). Confirming this, a subgroup analysis suggested that virus-positive patients with suspected myocarditis and cardiomyopathy may have a worse prognosis where no specific treatment is used or right ventricular EMB is performed.

Figulla et al. \[[@B9]\] and Karatolios et al. \[[@B15]\] used specific treatments on their patients during their studies \[antiviral therapy as an antiviral treatment (e.g., intravenous immunoglobulin, interferon) for virus-positive patients and an immunosuppressive drug for virus-negative patients\]. In a 2016 meta-analysis of nine randomized controlled trial studies it was found that patients who were administered a specific treatment showed a significant improvement in cardiac function compared with those who were given a placebo (difference = 0.10, 95% CI = 0.00--0.21), but there was no significant difference in mortality or heart transplantation between the two groups (odds ratio = 1.33, 95% CI = 0.77--2.31) \[[@B18]\]. Therefore, specific treatment may have been one source of the heterogeneity in the present study.

Subgroup analysis also indicated that the detection of virus-positive tissues in a right ventricular biopsy was associated with a worse prognosis. Yilmaz et al. \[[@B19], [@B20]\] previously found that biventricular biopsy has a higher diagnostic value for myocarditis and cardiomyopathy than a selective single-ventricular biopsy (*P* \< 0.001) and that in the case of biventricular biopsy, the left ventricular tissue appeared to be more diagnostically relevant than the right ventricular tissue (18.7% vs. 7.9%, respectively; *P* = 0.002). None of the studies that were included in this meta-analysis undertook biventricular biopsies. Furthermore, three studies undertook right ventricular biopsies and two of the seven studies that undertook left ventricular biopsies included specific treatment, which may have had confounding effects. Therefore, further research is required to determine whether right ventricular biopsy is more valuable for judging the prognosis.

Eight of the studies used PCR to detect viruses. However, Why et al. \[[@B8]\] and Figulla et al. \[[@B9]\] used the less sensitive methods of molecular hybridization and in situ hybridization. The inclusion of these studies in the meta-analysis caused the heterogeneity to reach 47%. However, the detection method was not found to have a significant effect on the results in the subgroup analysis.

This meta-analysis had the following limitations: (1) subjects who had received a heart transplantation or who were younger than 18 years of age were excluded from the analysis; (2) all of the studies included in the analysis were cohort studies, some sample sizes were small, and a loss of bias was unavoidable; (3) no-transplant survival was used as the observed outcome, with studies that included cardiac function and ventricular size changes as endpoints not being included; (4) nonenglish literature was excluded from the analysis and most of the research data came from European populations, with only one Asian population from Japan being included; (5) none of the studies conducted a second EMB before the end of the follow-up period so it was not possible to know whether the virus persisted in the myocardium and its effect on function; and (6) the follow-up times varied substantially between the studies. In addition, it should be noted that Why et al.\'s study \[[@B8]\] included a 6-year-old child. However, we believe that this will not have had a significant impact on the results of the study and that there may have been a greater bias had it been excluded. Furthermore, studies involving cardiac amyloidosis were not included in the present analysis because of their poor prognosis and the fact that they are prone to false positives \[[@B20], [@B21]\].

Few studies have investigated the impact of myocardial viruses on survival prognosis to date. Therefore, larger, multicenter cohort studies are required to gain a better understanding of this.

5. Conclusions {#sec5}
==============

In conclusion, the presence of a virus in the myocardium appears to have no effect on the long-term prognosis of patients with suspected myocarditis or dilated cardiomyopathy. However, subgroup analysis showed that this was a risk factor for poor prognosis in patients who did not receive specific treatment or who underwent right ventricular biopsy, suggesting that active antiviral therapy may improve the prognosis of virus-positive patients with cardiomyopathy. At the same time, an early myocardial biopsy to rule out the presence of viral infections in the myocardium will help to assess the prognosis and adjust the treatment strategies when considering myocarditis or cardiomyopathy in the case of unexplained heart failure.
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###### 

Detailed characteristics of studies included in the meta-analysis.

  Study                                Country          Study period   Follow period (months)   Patients      Mean age      Diagnosis                     Virus                                     Method                    Study outcome
  ------------------------------------ ---------------- -------------- ------------------------ ------------- ------------- ----------------------------- ----------------------------------------- ------------------------- -------------------------------------
  Why, H. J. F. et al. 1994            United Kingdom   1985--1989     11--50                   Virus+: 40    44.9          MC/DCM                        EV                                        Molecular hybridization   Virus-positive has bad prognosis
  Virus−: 76                                                                                                                                                                                                                  
  Figulla, H. R. et al. 1995           Germany          1987--1992     25.8 ± 13.7              Virus+: 20    48.2          IDCM                          EV                                        In situ hybridization     Virus-positive has better prognosis
  Virus−: 57                                                                                                                                                                                                                  
  Fujioka, et al. 2000                 Japan            1997--1998     6--12                    Virus+: 9     49 ± 18       IDCM                          EV                                        PCR                       Virus-positive has bad prognosis
  Virus−: 17                                                                                                                                                                                                                  
  Caforio, A. L. P. et al. 2007        Italy            1992--2005     10--54                   Virus+: 31    36 ± 18       AMC/BMC                       HCV/EV/PVB19/ADV/EBV/HSV/CMV/MUMPS        PCR                       Virus-positive has bad prognosis
  Virus−: 89                                                                                                                                                                                                                  
  Kindermann, I. et al. 2008           Germany          1994--2007     59 ± 42                  Virus+ : 79   42 ± 15       Suspected viral myocarditis   EV/PVB19/ADV/EBV/HHV6                     PCR                       Survival NO difference
  Virus−: 101                                                                                                                                                                                                                 
  Nowalany-Kozielska, E. et al. 2016   Poland           2004--2007     10.8--61.2               Virus+: 32    44.9 ± 10.7   DCM                           HCV/CVB/PVB19/CMV                         PCR                       Survival NO difference
  Virus−: 10                                                                                                                                                                                                                  
  Tebbe, U. et al. 2016                Germany          2003--2013     120                      Virus+: 17    54            CM                            HCV/EV/HHV6/PVB19/ADV/EBV/INFAB/HSV/VZV   PCR                       Survival NO difference
  Virus−: 40                                                                                                                                                                                                                  
  Karatolios, K. et al. 2017           Germany          2004--2008     58.2 ± 19.8              Virus+: 16    51.1 ± 11.6   DCM                           PVB19/CMV/HSV                             PCR                       Survival NO difference
  Virus−: 39                                                                                                                                                                                                                  
  Kuethe, F. et al. 2017               Germany          1997--2008     120                      Virus+: 167   47.7 ± 12.6   CHF/MC/DCM                    PVB19/EV/ADV/                             PCR/RT-PCR                Survival NO difference
  Virus−: 126                                                                                                                                                                                                                 
  Hjalmarsson, C. et al. 2019          Sweden                          112 ± 57                 Virus+: 29    47 ± 12       IDCM                          PVB19                                     PCR                       Survival NO difference
  Virus−: 11                                                                                                                                                                                                                  

MC: myocarditis, CHF: congestive heart failure, CM: cardiomyopathy, DCM/iDCM: dilated/idiopathic dilated cardiomyopathy, VZV: varicella-zoster virus, MUMPS: mumps virus, HSV: herpes simplex virus, EBV: epstein--Barr virus, HHV6: human herpes virus 6, ADV: adenovirus, INFA/B: InfluenzaA/B, CMV: cytomegalovirus, HCV: hepatitis C virus, PVB19: parvovirus-B19, PCR: polymerase chain reaction, RT-PCR: reverse transcription-polymerase chain reaction.

###### 

Baseline data for studies included in meta-analysis.

  Study                                Arrhythmia∆           Echocardiography      Cardiac index (L/min/m2)   Heart failure duration (months)   New York Heart Association (NYHA)                                                                 
  ------------------------------------ --------------------- --------------------- -------------------------- --------------------------------- ----------------------------------- ------------------- --------------- ------------ ------------ ------------
  Why, H. J. F. et al. 1994            Virus+: 8             Virus+: 38.9 ± 18.0   \-                         Virus+: 18.2 ± 9.8                \-                                  Virus+: 7.8 ± 9.6   Virus+: 0       Virus+: 9    Virus+: 16   Virus+: 16
  Virus−: 22                           Virus−: 36.2 ± 17.0   Virus−: 19.9 ± 10.0   Virus−: 14.9 ± 19.0        Virus−: 1                         Virus−: 21                          Virus−: 33          Virus−: 24                                
  Figulla, H. R. et al. 1995           Virus+: 7             Virus+: 35            Virus+: 66                 \-                                \-                                  25                  Virus+: 20      Virus+: 45   Virus+: 30   Virus+: 5
  Virus−: 8                            Virus−: 34            Virus−: 64            Virus−: 16                 Virus−: 47                        Virus−: 35                          Virus−: 2                                                     
  Fujioka, S. et al. 2000              \-                    Virus+: 17.8 ± 6.6    Virus+: 80.4±7.9           \-                                \-                                  \-                  0               0            Virus+: 2    Virus+: 7
  Virus−: 18.4 ± 7.4                   Virus−: 79.9 ± 11.1   Virus−: 5             Virus−: 12                                                                                                                                                     
  Caforio, A. L. P. et al. 2007        22                    Virus+:38 ± 14        \-                         12                                Virus+: 2.9                                             80              27           56           11
  Virus−: 45 ± 14                      Virus−: 3.2                                                                                                                                                                                                
  Kindermann, I. et al. 2008           \-                    37.7 ± 18.5           36.2 ± 6.90                15.6 ± 7.40                       \-                                  \-                  39              52           73           17
  Nowalany-Kozielska, E. et al. 2016   5                     Virus+: 36.3 ± 14.7   Virus+: 59.6 ± 12.9        \-                                                                    19.2 ± 6.4          Average NYHA:                             
  Virus−: 37.2 ± 12.2                  Virus−: 57.9 ± 11.1   Virus+: 1.9 ± 0.8                                                                                                                                                                    
  Virus−: 2.0 ± 0.8                                                                                                                                                                                                                               
  Tebbe, U. et al. 2016                \-                    50                    \-                         \-                                \-                                  \-                  \-              \-           \-           \-
  Karatolios, K. et al. 2017           \-                    29.2 ± 8.5            70.1 ± 9.2                 19.2 ± 8.8                        \-                                  \-                  4               23           25           3
  Kuethe, F. et al. 2017               \-                    33.3 ± 13.5           63.6 ± 9.0                 20.9 ± 9.2                        2.1 ± 0.8                           \-                  48              15           125          30
  Hjalmarsson, C. et al. 2019          \-                    Virus+: 27 ± 13       \-                         \-                                Virus+: 2.3 ± 0.86                  Virus+: 31 ± 15     Virus+: 3       Virus+: 9    Virus+: 10   Virus+: 7
  Virus−: 26 ± 12                      Virus−: 2.0 ± 0.49    Virus−: 7 ± 8         Virus−: 0                  Virus−: 4                         Virus−: 5                           Virus−: 2                                                     

∆: Atrial fibrillation and arrhythmia of nonsinus rhythm, LVEF: left ventricular ejection fraction, LVEDD: left ventricular end-diastolic dimension, LVEDP: left ventricular end-diastolic pressure.

###### 

Assessment of the cohort studies by Newcastle-Ottawa scale.

  Study (year)                         Selection   Comparability   Outcome   Total scores                    
  ------------------------------------ ----------- --------------- --------- -------------- ---- --- --- --- ---
  Why, H. J. F. et al. 1994            ★           ★               ★         ★              ★★   ★   ★   ★   9
  Figulla, H. R. et al. 1995           ★           ★               ★         ★              ★☆   ★   ★   ☆   7
  Fujioka, et al. 2000                 ★           ★               ★         ★              ★★   ★   ☆   ★   8
  Caforio, A. L. P. et al. 2007        ★           ★               ★         ☆              ★☆   ★   ★   ★   7
  Kindermann, I. et al. 2008           ★           ★               ★         ★              ★☆   ★   ★   ★   8
  Nowalany-Kozielska, E. et al. 2016   ★           ★               ★         ☆              ★★   ★   ★   ★   8
  Tebbe, U. et al. 2016                ★           ★               ★         ★              ★★   ★   ★   ☆   8
  Karatolios, K. et al. 2017           ★           ★               ★         ★              ★☆   ★   ★   ☆   7
  Kuethe, F. et al. 2017               ★           ★               ★         ★              ★★   ★   ★   ☆   8
  Hjalmarsson, C. et al. 2019          ★           ★               ★         ★              ★★   ★   ★   ★   9

###### 

The value in publication bias.

  Std_Eff   Coef.      Std. Err.   *t*     *P* \> \|*t*\|   \[95% Conf. Interval\]   
  --------- ---------- ----------- ------- ---------------- ------------------------ ----------
  Slope     −0.08622   0.423287    −0.20   0.844            −1.062322                0.889882
  Bias      0.86987    0.994077    0.88    0.407            −1.422481                3.162211

[^1]: Academic Editor: Brian Tomlinson
